Latest News

Standalone costs trim margins even as revenue grows 7.4% and profit guidance rises.

A major Arizona project decision came alongside record quarterly results.

Management pairs a Texas expansion with new multiyear targets.

Jensen Huang's departure revives a longstanding investor debate of the value of a founder. Can Nvidia deliver without him?

Hyperscaler deployments are accelerating, and management lifted its full-year outlook.

Plozasiran launch prep and a multibillion sHTG opportunity come into focus.

Upfront capital falls $500 million as NOAA certification approaches.

Operating costs fell sharply as its handheld heart monitor advanced through FDA review.

Affiliate growth and AI licensing deals fueled results, with a one-time fee adding a notable lift.

J.B. Hunt Transport Services (NASDAQ:JBHT) plans to emphasize margin improvement as it pursues growth in its intermodal and dedicated businesses, executives said at an investor conference. Chief Financial Officer Brad Delco said the company’s need for drivers has reached or exceeded pandemic-era le

SKYX Platforms (NASDAQ:SKYX) reported record third-quarter revenue of $25.7 million and a narrower operating cash outflow, while executives outlined plans to expand sales to homebuilders following its merger with Deako. Revenue rose 7.4% from $23.9 million a year earlier, marking the company’s 11th

Rank One Computing (NASDAQ:ROC) reported record third-quarter revenue and its first profitable quarter since its February initial public offering, as federal contract activity and software licensing helped lift sales. Revenue rose 50% from a year earlier to $8 million in the quarter ended Sept. 30,

Corteva (NYSE:CTVA) lowered its full-year earnings outlook after a sharp deterioration in Brazil’s agricultural market and elevated inventories in the distribution channel outweighed growth in other regions. The company now expects 2026 adjusted pro forma operating EBITDA of $1.1 billion to $1.125

Relmada Therapeutics (NASDAQ:RLMD) expects to submit applications for its bladder cancer treatment candidate NDV-01 and Prader-Willi syndrome program sepranolone by the end of 2026, executives said on the company’s third-quarter earnings call. Chief Executive Officer Sergio Traversa said progress o

KBE carries a lower fee and higher yield, yet FTXO's concentrated 50-stock portfolio tells a different story about risk and reward.

The utility is allocating infrastructure costs to data center operators, protecting existing customers from financial strain as grid expansion accelerates.

Don't assume your portfolio is diversified.

Live Nation Entertainment (NYSE:LYV) outlined plans to expand its venue portfolio, increase ticket sales and use artificial intelligence to reach more concertgoers, as executives presented their case for continued double-digit profit growth. The company expects its venue investment strategy to gene

Proficient Auto Logistics (NASDAQ:PAL) reported higher third-quarter revenue following its acquisition of Hansen & Adkins, but profitability declined as fuel costs outpaced customer surcharges and driver shortages constrained capacity. Revenue rose 30.3% from a year earlier to $149 million in t

StoneCo (NASDAQ:STNE) lowered its 2026 profit outlook and withdrew its previously communicated 2027 targets, citing persistently high interest rates, higher-than-expected credit losses and the near-term cost of retaining merchants. The payments and financial services company reported gradual improv

Shimmick (NASDAQ:SHIM) returned to profitability in the third quarter of 2026, reporting its first positive net income in 12 quarters as new projects ramped up and the infrastructure contractor continued to wind down lower-margin work. The company reported approximately $0.9 million in net income,

Andersen Group (NYSE:ANDG) raised its 2026 revenue and adjusted earnings outlook after reporting third-quarter revenue growth of 18.7%, and issued a 2027 forecast that anticipates roughly 30% revenue growth as it expands through acquisitions. Third-quarter revenue rose to approximately $337 million

Nektar Therapeutics (NASDAQ:NKTR) said it has initiated three Phase III studies of its experimental drug rezpegaldesleukin, or REZPEG, in atopic dermatitis and expects to begin a pivotal alopecia areata study in December, earlier than previously planned. On its third-quarter 2026 earnings call, the

Sensus Healthcare (NASDAQ:SRTS) reported lower third-quarter revenue despite shipping more superficial radiation therapy systems, as product mix and the absence of sales to its historically largest customer weighed on the top line. Revenue fell 13% to $6 million from $6.9 million a year earlier, wh

NeuroPace (NASDAQ:NPCE) cut its full-year revenue outlook after third-quarter sales fell short of management’s expectations, as disruptions at major treatment centers and changes to its sales organization slowed procedures using its RNS System. The company reported third-quarter revenue of $23.1 mi